RCKT vs REPL

Rocket Pharmaceuticals, Inc. vs Replimune Group, Inc. — Valuation Comparison 2026

RCKT

Biotechnology
Rocket Pharmaceuticals, Inc.
Quality
4.6
out of 10
Value Trap
31
LOW
Price
$3.02
Last close
Models
7/13
Active
VS

REPL

Biotechnology
Replimune Group, Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$4.68
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType RCKT Fair ValueRCKT Upside REPL Fair ValueREPL Upside
Bayesian DCF Intrinsic $0.95 -68.5% $1.65 -64.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.19 -60.5% $2.21 -52.7%
Dynamic NAV Asset-Based $1.67 -44.6% $3.58 -23.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RCKT vs REPL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RCKT vs REPL — Which Stock Is More Undervalued?

RCKT scores higher with a 4.6/10 quality rating vs REPL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rocket Pharmaceuticals, Inc. (RCKT) and Replimune Group, Inc. (REPL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RCKT currently trades at $3.02 with a QOC of 4.6/10, while REPL trades at $4.68 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).